Sei Investments Co. Buys 6,706 Shares of Cencora, Inc. $COR

Sei Investments Co. increased its stake in Cencora, Inc. (NYSE:COR) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 528,528 shares of the company’s stock after purchasing an additional 6,706 shares during the period. Sei Investments Co.’s holdings in Cencora were worth $165,190,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of COR. Norges Bank bought a new stake in shares of Cencora in the second quarter valued at about $695,215,000. Mizuho Markets Americas LLC boosted its position in shares of Cencora by 116.4% during the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after buying an additional 1,511,906 shares during the period. Artisan Partners Limited Partnership bought a new position in shares of Cencora during the second quarter worth about $411,888,000. Vanguard Group Inc. grew its holdings in shares of Cencora by 5.3% during the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Finally, Viking Global Investors LP raised its position in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This trade represents a 12.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,220 shares of company stock worth $5,282,867 over the last quarter. 0.38% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Barclays upped their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a report on Tuesday, January 13th. Wells Fargo & Company boosted their price objective on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Finally, Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Stock Up 0.6%

COR stock opened at $352.39 on Friday. The company has a market cap of $68.55 billion, a price-to-earnings ratio of 42.35, a P/E/G ratio of 1.63 and a beta of 0.68. Cencora, Inc. has a twelve month low of $252.49 and a twelve month high of $377.54. The business has a 50 day moving average price of $355.37 and a two-hundred day moving average price of $337.70. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.73 EPS. Analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.